Journal of Clinical Endocrinology & Metabolism, Vol 81, 2930-2933, Copyright © 1996 by Endocrine Society

ARTICLES

Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study

L Bartalena, S Brogioni, L Grasso, F Bogazzi, A Burelli and E Martino
Istituto di Endocrinologia, University of Pisa, Italy.

Amiodarone-induced thyrotoxicosis (AIT) occurs in both abnormal (type I) and apparently normal (type II) thyroid glands due to iodine-induced excessive thyroid hormone synthesis in patients with nodular goiter or latent Graves' disease (type I) or to a thyroid-destructive process caused by amiodarone or iodine (type II). Twenty-four consecutive AIT patients, 12 type I and 12 type II, were evaluated prospectively. Sex, age, severity of thyrotoxicosis, and cumulative amiodarone dose were similar. Type II patients had higher serum interleukin-6 (IL-6; median, 440 vs. 173 fmol/L; P < 0.001), but lower serum thyroglobulin levels. Several weeks of thionamide therapy in eight type II or prolonged glucocorticoid administration in two type I patients had previously failed to control hyperthyroidism. Type II patients were given prednisone (initial dose, 40 mg/day) for 3 months and achieved normal free T3 and IL-6 after an average of 8 and 6 days, respectively. Exacerbation of thyrotoxicosis with increased serum IL-6 values, observed in 4 patients while tapering steroid, was promptly corrected by increasing it. Type I patients, given methimazole (30 mg/day) and potassium perchlorate (1 g/day), achieved normal free T3 and IL-6 concentrations after an average of 4 weeks. Exacerbation of thyrotoxicosis with markedly increased IL-6 was controlled by prednisone in 3 of 4 cases. Distinction of different forms of AIT is essential for its successful management. Type II AIT should be treated with glucocorticoids; type I AIT should be treated with methimazole and potassium perchlorate. Exacerbation of thyrotoxicosis, which may occur in both forms and is probably related to destructive processes, should be controlled by the addition/increase in glucocorticoids.

This article has been cited by other articles:

				I. Klein and S. Danzi Thyroid Disease and the Heart Circulation, October 9, 2007; 116(15): 1725 - 1735. [Abstract] [Full Text] [PDF]

				D. Conen, L. Melly, C. Kaufmann, S. Bilz, P. Ammann, B. Schaer, C. Sticherling, B. Muller, and S. Osswald Amiodarone-Induced Thyrotoxicosis: Clinical Course and Predictors of Outcome J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2350 - 2355. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, L. Tomisti, G. Rossi, M. L. Tanda, E. Dell'Unto, F. Aghini-Lombardi, and E. Martino Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 556 - 562. [Abstract] [Full Text] [PDF]

				A. J O'Sullivan, M. Lewis, and T. Diamond Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur. J. Endocrinol., April 1, 2006; 154(4): 533 - 536. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, C. Cosci, S. Brogioni, E. Dell'Unto, L. Grasso, F. Aghini-Lombardi, G. Rossi, A. Pinchera, L. E. Braverman, et al. Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1999 - 2002. [Abstract] [Full Text] [PDF]

				H. Xiao, W. Zhuang, S. Wang, B. Yu, G. Chen, M. Zhou, and N. C. W. Wong Arterial Embolization: A Novel Approach to Thyroid Ablative Therapy for Graves' Disease J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3583 - 3589. [Abstract] [Full Text] [PDF]

				F. Osman, J. A. Franklyn, M. C. Sheppard, and M. D. Gammage Successful Treatment of Amiodarone-Induced Thyrotoxicosis Circulation, March 19, 2002; 105(11): 1275 - 1277. [Abstract] [Full Text] [PDF]

				E. Martino, L. Bartalena, F. Bogazzi, and L. E. Braverman The Effects of Amiodarone on the Thyroid Endocr. Rev., April 1, 2001; 22(2): 240 - 254. [Abstract] [Full Text]

				I. Klein and K. Ojamaa Thyroid Hormone and the Cardiovascular System N. Engl. J. Med., February 15, 2001; 344(7): 501 - 509. [Full Text] [PDF]

				G. H. Daniels Amiodarone-Induced Thyrotoxicosis J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 3 - 8. [Full Text]

				T. Di Matola, F. D’Ascoli, G. Fenzi, G. Rossi, E. Martino, F. Bogazzi, and M. Vitale Amiodarone Induces Cytochrome c Release and Apoptosis through an Iodine-Independent Mechanism J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4323 - 4330. [Abstract] [Full Text]

				K.-C. Loh Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review Postgrad. Med. J., March 1, 2000; 76(893): 133 - 140. [Abstract] [Full Text]

				J. Wolff Perchlorate and the Thyroid Gland Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106. [Abstract] [Full Text] [PDF]

				C M Newman, A Price, D W Davies, T A Gray, and A P Weetman Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy Heart, February 1, 1998; 79(2): 121 - 127. [Full Text]